NCT01810380View on ClinicalTrials.gov

Brexpiprazole in Patients With Acute Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

Placebo

Once daily as tablets and capsules, orally

DRUG

Brexpiprazole

2-4 mg/day, once daily, tablets, orally

DRUG

Quetiapine extended release

400-800 mg/day, once daily, encapsulated tablets, orally

Trial Locations (1)

92025

US009, Escondido

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

H. Lundbeck A/S

INDUSTRY